Redeye interviews Ultimovacs' CEO Carlos de Sousa and CMO Jens Bjørheim. We discuss the recently communicated three-year survival readout for cohort 1 of the company's UV1-103 trial. Further, we discuss the company's clinical and business development strategy going forward.